Synthetic modification of PAN membrane: biocompatibility and functional characterization

Area of Science:

• Nephrology
• Biomaterials Science
• Clinical Immunology

Background:

• Polysulfone (PAN) membranes in hemodialysis can interact with the bradykinin system, especially with angiotensin-converting enzyme inhibitors.
• A modified membrane, SPAN (special PAN), was developed to mitigate this interaction by altering polymer composition.
• Ensuring SPAN maintains the biocompatibility of the original PAN membrane is crucial for clinical application.

Purpose of the Study:

• To evaluate the clinical biocompatibility and performance of the novel SPAN hemodialysis membrane.
• To compare SPAN against a standard polysulfone (F60S) and the original PAN membrane in a clinical setting.

Main Methods:

• A clinical study involving nine patients undergoing hemodialysis.
• Comparison of three dialyzer membranes: F60S (polysulfone), PAN, and SPAN.
• Assessment of biocompatibility markers including complement activation (C5a, terminal complement complex), white blood cell count, platelet count, and thrombin-anti-thrombin complex.

Main Results:

• All three dialyzers showed minimal, clinically acceptable increases in C5a.
• Terminal complement complex, white blood cell, and platelet counts remained stable across all membranes.
• Arterial and venous thrombin-anti-thrombin complex levels were similar for F60S, PAN, and SPAN, with comparable urea clearances between F60S and SPAN.

Conclusions:

• The modified SPAN membrane demonstrates satisfactory biocompatibility, similar to highly biocompatible synthetic membranes like F60S.
• SPAN effectively mitigates the bradykinin generation issue associated with PAN membranes without compromising clinical performance.
• SPAN represents a promising alternative hemodialysis membrane with an improved safety profile.